8-K
filed June 17, 2026, 5:28 PM ET
ticker PKTX
CIK 0001128189
leadership
confidence high
sentiment positive
materiality 0.70
ProtoKinetix appoints new President, forms SightPath Biotech, patents valued at $253M
ProtoKinetix, Inc.
- Director McDonough resigned March 31; June 17: Jones, Lamp, Brunt appointed directors, Brunt as President.
- Formed SightPath Biotech LLC for dry-eye drug PKX-001; patent valuation ~$253M per IQVIA & Benoit & Cote studies.
- Late filings: 2025 10-K (Mar 31) and Q1 2026 10-Q (May 15); company still working to complete.
- Repriced 61.19M options and 6M warrants from $0.028 to $0.01, extended expiry to Dec 2030.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Edward McDonough resigned as Director at ProtoKinetix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 31, 2026, Mr. Edward McDonough, after serving many years as a trusted advisor to ProtoKinetix, Incorporated (the “Company”) under the leadership of Clarence E. Smith, notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Brunt was appointed as Director at ProtoKinetix, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Brunt was appointed as President at ProtoKinetix, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Jones was appointed as Director at ProtoKinetix, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jason Lamp was appointed as Director at ProtoKinetix, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.